Related by context. All words. (Click for frequent words.) 69 neuroendocrine tumors 67 epithelial tumors 66 neuroendocrine cancers 66 metastatic tumors 66 metastatic cancer 66 hematologic disorders 65 solid tumors 65 metastatic lesions 64 skeletal metastases 64 liver metastases 64 malignancies 64 proliferative disorders 64 Glioblastoma multiforme 64 metastatic liver 63 metastases 63 hepatocellular carcinoma 63 pancreatic adenocarcinoma 63 myeloma cells 63 pancreatic cancers 62 carcinoma HCC 62 carcinoid tumors 62 carcinoid 62 tumors 62 lung tumors 62 metastatic 62 myelofibrosis polycythemia vera 62 renal tumors 62 cancers 62 malignant pleural mesothelioma 62 hepatocellular carcinoma HCC 61 gastric cancers 61 unresectable tumors 61 metastatic disease 61 FLT3 61 Candida infection 61 prostate carcinomas 61 hormone gastrin 61 tumor metastases 61 adenocarcinomas 61 precursor lesions 61 hematological diseases 61 epithelial cancers 61 distant metastasis 61 neoplasia 61 renal cell carcinoma 61 Metastatic 60 bladder cancers 60 metastatic neuroendocrine tumors 60 nasopharyngeal carcinoma 60 colorectal carcinoma 60 gastrointestinal stromal tumor 60 Carcinoid tumors 60 hepatocellular cancer 60 breast carcinomas 60 cirrhosis liver failure 60 K ras mutations 60 Glioblastoma 60 immunological diseases 60 Hepatocellular Carcinoma HCC 60 hepatitis C viral infection 60 AA amyloidosis 60 myeloproliferative disorders 60 prostate adenocarcinoma 60 malignant pheochromocytoma 60 curable cancers 60 chronic viral infections 60 peritoneal carcinomatosis 60 Glioblastoma Multiforme 60 prognostic marker 60 chemo resistant 60 kidney urologic 60 BRAF mutation 60 hematologic malignancies 60 BCR ABL mutations 60 carcinoma 60 CYT# potent vascular disrupting 60 chemoresistant 60 gastrointestinal stromal tumors 59 metastatic gastric 59 liver fibrosis 59 fallopian tube carcinoma 59 molecular abnormalities 59 anti angiogenic therapy 59 tumor recurrence 59 malignancy 59 GISTs 59 WT1 59 gastrointestinal cancers 59 metastatic malignant melanoma 59 cell carcinoma 59 metastatic melanoma 59 TTR amyloidosis 59 EGFR inhibitors 59 Gliomas 59 metastatic colorectal 59 liver metastasis 59 imatinib resistance 59 gastric carcinoma 59 fibrotic disease 59 metastatic bladder 59 gastric adenocarcinoma 59 pre malignant lesions 59 Cholangiocarcinoma 59 ovarian lung 59 histologies 59 myeloproliferative diseases 59 KRAS mutation 59 Chronic myeloid leukemia CML 59 pancreatic lung 59 neuroblastoma tumors 59 Acute myeloid leukemia 59 glioblastoma tumor 58 systemic amyloidosis 58 cisplatin chemotherapy 58 HNSCC 58 urothelial carcinoma 58 activated lymphocytes 58 GIST tumors 58 adrenocortical cancer 58 activating mutations 58 mitochondrial disorders 58 molecular biomarkers 58 neuro degenerative disease 58 Epstein Barr virus EBV 58 renal carcinoma 58 cytotoxic agents 58 malignant lymphomas 58 serous ovarian cancer 58 gastrointestinal stromal tumors GISTs 58 prognostic markers 58 prostate breast 58 investigational therapies 58 immunodeficiency disorders 58 lung carcinomas 58 cholangiocarcinoma 58 myeloproliferative disorder 58 malignant fibrous histiocytoma 58 RNAi therapeutic targeting 58 Metastatic breast cancer 58 glioblastoma multiforme GBM 58 mycosis fungoides 58 cytoreduction 58 metastatic prostate cancer 58 Squamous 58 kidney fibrosis 58 GBM tumors 58 HER2 positive breast cancer 58 Alessandro Riva 58 recurrent NSCLC 58 papillary renal cell carcinoma 58 essential thrombocythemia 58 taxane chemotherapy 58 premalignant lesions 58 neoadjuvant therapy 58 Glioblastoma Multiforme GBM 58 antiproliferative effects 58 lymphoid organs 58 lymphomas 58 myeloproliferative neoplasms 58 depsipeptide 58 neoplasm 58 OHR/AVR# 58 CMV disease 58 graft dysfunction 58 leukemia AML 58 metastatic RCC 58 cisplatin resistant 58 leukemias lymphomas 58 mucinous 58 pleural mesothelioma 58 recurrent ovarian cancer 58 ovarian tumors 58 EGFR mutation 58 ADPKD 58 NF kB pathway 58 HBV replication 58 anemias 58 recurrent prostate cancer 58 carcinomas 58 systemic scleroderma 58 gastrointestinal stromal tumor GIST 58 breast pancreatic 58 angiosarcoma 58 androgen receptor AR 58 TTR gene 58 Glioblastoma multiforme GBM 58 renal cell carcinomas 58 eIF 4E 58 breast cancer metastasis 58 colorectal tumors 58 sarcomas 58 carcinoid tumor 58 hematological disorders 58 prostate carcinoma 58 lung pancreatic 58 paragangliomas 58 prostate cancers 58 metastatic pancreatic 58 colorectal adenocarcinoma 58 lymphoid cells 58 Surgical resection 57 intracranial tumors 57 noncancerous cells 57 hamartomas 57 cervical carcinoma 57 stem cells CSCs 57 metastasis 57 basal cell carcinoma BCC 57 HER2 positive 57 unresectable 57 carcinoids 57 colorectal cancer CRC 57 tumors GIST 57 oncoproteins 57 metastatic renal cell carcinoma 57 bone metastasis 57 neoplasms 57 metastatic colon cancer 57 cellular pathways 57 Hurthle cell 57 metastatic melanomas 57 tyrosine kinase inhibitors 57 metastatic lymph nodes 57 PKCi 57 pediatric malignancies 57 MALT lymphoma 57 standard chemotherapy regimens 57 Immunosuppressive drugs 57 squamous cell lung cancer 57 isotypes 57 malignant tumors 57 Gleevec resistant 57 leukemic cells 57 NSCLC 57 lymphoma subtypes 57 HAAH 57 liver cancer 57 cachexia 57 glioblastomas 57 metastatic brain tumor 57 carcinoid cancer 57 Chronic lymphocytic leukemia 57 immune modulator 57 motor neuron diseases 57 esophagogastric junction 57 GBMs 57 transplantation HCT 57 hematological cancers 57 Proxinium TM 57 colorectal cancers 57 malignant growths 57 prostate cancer CaP 57 cystic lesions 57 resectable 57 refractory acute myeloid 57 neoplastic 57 chemotherapeutic agents 57 demyelinating diseases 57 anti angiogenic agents 57 haematopoietic 57 osteosarcomas 57 malignant pancreatic 57 Myelofibrosis 57 diabetic nephropathy 57 gastrointestinal GI cancers 57 proto oncogene 57 biliary cancer 57 chemoradiotherapy 57 Metastatic colorectal cancer 57 pulmonary metastases 57 motor neuron degeneration 57 tumoral 57 V#F mutation 57 Xanafide 57 squamous 57 anti angiogenic drugs 57 Glioblastomas 57 lupus nephritis 57 PI3K AKT 57 breast endometrial 56 HepDirect prodrug 56 diagnostic biomarkers 56 hyperoxaluria 56 squamous cell carcinoma SCC 56 Insegia 56 myelofibrosis 56 bone marrow suppression 56 systemic fungal infections 56 Vicinium TM 56 protein kinase inhibitor 56 kinase inhibition 56 immunomodulatory therapy 56 lung ovarian 56 lung fibrosis 56 pancreatic ovarian 56 glioblastoma 56 curative resection 56 prognostic indicator 56 mutational status 56 paraganglioma 56 mTOR inhibitors 56 imatinib Gleevec 56 multiple myeloma MM 56 malignant transformation 56 grade gliomas 56 SOD1 gene 56 Metastases 56 Li Fraumeni Syndrome 56 EGFr 56 small molecule inhibitors 56 predictive biomarkers 56 malignant lymphoma 56 antibody mediated 56 castrate resistant prostate cancer 56 breast carcinoma 56 hematopoietic cell 56 BCG refractory 56 endometrial cancers 56 TNFa 56 squamous cell 56 presymptomatic 56 antiangiogenic agent 56 malignant ascites 56 recurrent glioblastoma multiforme GBM 56 colorectal gastric 56 Her2 56 chemotherapeutic 56 medullary thyroid cancer 56 glioma cells 56 FGFR1 56 Carcinoma 56 non alcoholic steatohepatitis 56 microsphere therapy 56 esophageal cancers 56 seminoma 56 small molecule activators 56 colon esophageal 56 MMP inhibitors 56 Glioma 56 prostate cancer PCa 56 DCVax 56 neurodegenerative disorder 56 virotherapy 56 prostate pancreatic 56 Medullary thyroid cancer 56 NSCLC tumors 56 JAK3 56 pituitary adenomas 56 EGF receptor 56 ADAMTS# 56 monogenic 56 recurrent glioblastoma multiforme 56 Flt3 56 hormone refractory 56 diagnostic biomarker 56 ovarian breast 56 EpCAM 56 cervical lymph nodes 56 nonsmall cell lung cancer 56 gynecological cancers 56 aplasia 56 MAPK pathway 56 brain tumor glioblastoma multiforme 56 MEK inhibitors 56 acute GvHD 56 cytoreductive surgery 56 apoptotic pathway 56 node metastasis 56 ALK inhibitor 56 Kupffer cells 56 cutaneous melanoma 56 NF2 56 Radiofrequency ablation 56 cell lung cancer 56 histological subtypes 56 hepatic tumors 56 Basal cell 56 humanized monoclonal antibodies 56 chondrosarcoma 56 biliary strictures 56 familial amyloidotic polyneuropathy FAP 56 fatal neurodegenerative disorder 56 pancreatic NET 56 idiopathic pulmonary fibrosis IPF 56 Prion diseases 56 EGFR mutations 56 Helicobacter pylori H. pylori 56 Sezary syndrome 56 synovial sarcoma 56 micrometastases 56 thymic carcinoma 56 renal fibrosis 56 proliferative diseases 56 polyomavirus nephropathy 56 PARP inhibitors 56 neoplastic lesions 56 neuroblastomas 56 Radical prostatectomy 56 muscular dystrophies 56 therapeutic monoclonal antibody 56 metastatic kidney 56 B CLL 56 MYCN amplification 56 VEGF receptor 56 metastatic colorectal cancer 56 PI3K Akt 56 epithelial tissues 56 granzyme B 56 dirucotide MBP# 56 pancreatic islet cell 56 CTAP# Capsules 56 liver scarring 56 IRX 2 55 colorectal liver metastases 55 mitochondrial toxicity 55 vasculopathy 55 NKG2D 55 allograft rejection 55 Waldenstrom macroglobulinemia 55 selective inhibition 55 splice variants 55 cell lymphoma CTCL 55 erlotinib Tarceva ® 55 oral JAK1 55 colorectal cancer liver metastases 55 hepatoma 55 hematopoietic cells 55 colorectal lung 55 gastrointestinal stromal tumors GIST 55 activating mutation 55 tumor necrosis 55 androgen deprivation 55 hypophosphatasia 55 tumor metastasis 55 ductal adenocarcinoma 55 cancerous lesions 55 myelomas 55 trastuzumab Herceptin ® 55 radiolabeled antibodies 55 idiopathic pulmonary 55 epithelioid 55 distant metastases 55 β catenin 55 Leukemias 55 mesothelial cells 55 Malignant mesothelioma 55 chemopreventive agent 55 mesotheliomas 55 malignant neoplasm 55 BRAF inhibitors 55 premalignant 55 Ceflatonin 55 transgene expression 55 radiolabeled TM# 55 urothelial cancer 55 nonmelanoma skin cancers 55 neuroendocrine carcinoma 55 pancreatic endocrine 55 alkylating agents 55 cell lymphomas 55 PCNSL 55 pancreatic prostate 55 oncoprotein 55 brain metastases 55 immunocompetent 55 Epidermal Growth Factor Receptor 55 tumor antigens 55 scleroderma 55 PARP inhibition 55 genetic aberrations 55 induce apoptosis 55 chronic granulomatous disease 55 PNET 55 SGLT2 55 bone metastases 55 tumor cells 55 endostatin 55 advanced hepatocellular carcinoma 55 cyclin E 55 INxin 55 polycythemia vera PV 55 oligodendroglioma 55 lymphoma CTCL 55 lobular carcinoma 55 colon lung 55 myelodysplastic syndrome MDS 55 lymphatic tissue 55 Acute Radiation Syndrome ARS 55 Lupus nephritis 55 mutated KRAS gene 55 orthotopic model 55 bladder ovarian 55 inflammatory bowel diseases 55 targeted radiotherapeutic 55 uPA 55 IGF IR 55 leukaemic stem cells 55 transplant HSCT recipients 55 seminomas 55 extracranial 55 lymphoid 55 sclerosing 55 hypermethylation 55 neovascularisation 55 BRCA deficient 55 gefitinib Iressa 55 M2 subunit 55 basal cell cancers 55 recurrent metastatic 55 colon cancers 55 chemoresistance 55 radiofrequency ablation RFA 55 refractory metastatic 55 malignant pleural mesothelioma MPM 55 BrachySil TM 55 KIT mutations 55 signaling cascades 55 treating cancerous tumors 55 costimulatory 55 Gastric cancer 55 thymoma 55 chemokine receptors 55 Neurodegenerative diseases 55 neoplastic cells 55 plasma kallikrein 55 epithelial origin 55 castration resistant prostate cancer 55 Hodgkin lymphoma HL 55 Acute lymphoblastic leukemia 55 delay bone metastases 55 astrocytomas 55 interferon pathway 55 soft tissue sarcomas 55 radiation therapy SBRT 55 Li Fraumeni 55 Squamous cell 55 gastric cancer 55 metastatic carcinoma 55 epithelial ovarian 55 fibrosis cirrhosis 55 Enzastaurin 55 Akt activation 55 chromosome aberrations 55 leiomyomas 55 polyclonal antibodies 55 prostate cancer CRPC 55 SSc 55 idiopathic myelofibrosis 55 TGF b 55 PAOD 55 HCV infections 55 lung cancers 55 anaplastic 55 prophylactic cranial irradiation 55 Pulmonary arterial hypertension 55 pilocytic astrocytomas 55 CBLC# 55 lytic 55 chemotherapy induced neutropenia 55 herpesviruses 55 lymphocytic leukemia 55 p# mutations 55 neoplastic diseases 55 cathepsins 55 therapeutic monoclonal antibodies 55 gastroesophageal junction 55 erythropoiesis 55 immunohistochemical staining 55 Pseudomonas aeruginosa infections 55 hepatocellular carcinoma liver 55 fibrotic diseases 55 nodal metastasis 55 Hereditary angioedema HAE 55 CD# expressing 55 IDH mutations 55 Idiopathic pulmonary fibrosis 55 antisense inhibitors 55 pulmonary metastasis 55 curative therapy 55 medically inoperable 55 irinotecan chemotherapy 55 essential thrombocythemia ET 55 dexpramipexole 55 EGFR pathway 55 nephrotoxicity 55 TG# [003] 55 metastatic adenocarcinoma 55 intestinal polyps 55 primary immunodeficiencies 55 Systemic lupus erythematosus SLE 55 neoplasias 55 HbF 55 tumor antigen 55 Gleevec imatinib 55 refractory AML 55 somatic mutations 55 acute lymphoid leukemia 55 AEG# 55 endometrial adenocarcinoma 55 superficial bladder cancer 55 molecular subtypes 55 metastatic breast 55 EGFR tyrosine kinase inhibitors 55 radionuclide therapy 55 SOD1 55 BCR ABL protein 55 allogeneic bone marrow 55 IL 1β 55 colorectal cancer 55 KRAS oncogene 54 downregulating 54 carbohydrate antigens 54 hyperplastic 54 Gleevec imatinib mesylate 54 monoclonal antibody MAb 54 HuLuc# 54 cell acute lymphoblastic 54 relapsed ovarian cancer 54 selective inhibitors 54 Stat5 54 Sym# 54 CTGF 54 lymph node enlargement 54 pancreatic colon 54 histopathologic examination 54 Fas ligand 54 B Cell Lymphoma 54 cancerous tumors 54 histone deacetylase inhibitor 54 cytotoxic therapies 54 costimulation 54 gastric carcinomas 54 chemotherapeutic drugs 54 IGF 1R 54 receptor tyrosine kinase inhibitor 54 HER2 overexpression 54 Nephrotic Syndrome 54 TKI therapy 54 myopathies 54 CCR1 54 Follicular lymphoma 54 acute leukemias 54 AAV2 54 trial evaluating PRX# 54 HER2 neu 54 renal disease 54 differentiated thyroid 54 doxorubicin Transdrug R 54 sarcoma 54 Aplidin 54 Chronic pancreatitis 54 tumor suppressor protein 54 tyrosine kinase inhibitors TKIs 54 MGUS 54 cell lysis 54 anticancer therapies 54 inhibit metastasis 54 hedgehog pathway 54 prostate lung 54 cardiac allograft vasculopathy 54 hCG beta 54 GSK3 54 Aspergillus infections 54 commercialize deforolimus 54 acute myelogenous leukemia AML 54 KRAS status 54 bile duct cancers 54 ovarian prostate 54 metastatic ovarian cancer 54 recurrent glioblastoma 54 Cytoxan 54 LHRH receptor positive 54 preclinically 54 anticancer agents 54 gene rearrangements 54 anti apoptotic proteins 54 EGF receptors 54 mutated p# 54 potent inhibitors 54 leukemia ALL 54 ALN TTR 54 palliative radiotherapy 54 TRAIL induced apoptosis 54 cytotoxic chemotherapy 54 Ribavirin causes 54 chronic thromboembolic pulmonary 54 Hedgehog pathway 54 delta isoform 54 Kinase inhibitors 54 leiomyosarcoma 54 EGFRvIII 54 lysosomal 54 docetaxel Taxotere ® 54 pheochromocytoma 54 cellular immunotherapy 54 Circulating tumor cells 54 cardiac dysfunction 54 autoreactive T cells 54 RECAF tm 54 neurotrophic 54 anticancer therapy 54 LRP5 54 immune suppressive cells 54 Brain metastases 54 IMA# 54 hepatic fibrosis 54 oncogenesis 54 enzastaurin 54 pancreatic carcinoma 54 HCV infection 54 severe oral mucositis 54 vinca alkaloids 54 EGFR HER2 54 multidrug resistance 54 pancreatic tumors 54 adjuvant therapies 54 non resectable 54 tumor 54 leukaemias 54 lobular carcinomas 54 hormone receptor positive 54 GATA3 54 adenocarcinoma 54 cytoprotective 54 mesothelin 54 Symadex 54 p#HER# 54 hormone refractory prostate cancer 54 Bezielle 54 lymphoid tumors 54 cyclin dependent kinases CDKs 54 anti angiogenic therapies 54 oligodendrogliomas 54 malignant cells 54 necrotizing 54 carcinomatosis 54 precancerous condition 54 degenerative disorders 54 metastatic prostate 54 EGFR receptor 54 lung metastases 54 chromosomal mutations 54 adhesion molecule EpCAM expressing 54 testicular cancers 54 lung adenocarcinomas 54 immunoregulation 54 SCCHN 54 immunosuppressive regimens 54 hypoxic tumors 54 cervical intraepithelial neoplasia 54 micrometastasis 54 metastatic HER2 positive 54 metastatic breast cancer 54 Meningiomas 54 MyVax R 54 cetuximab Erbitux 54 Malignant tumors 54 KRAS mutant 54 Parkinsonian Syndromes 54 PIK3CA 54 Stereotactic radiosurgery 54 p# deficient 54 leukemia APL 54 photodynamic treatment 54 mucosal tissues 54 embryonal 54 sarcomatoid 54 metastatic malignant 54 chemotherapeutic regimens 54 DCVax R 54 FGFR2 54 autoimmune diseases 54 myeloproliferative disease 54 nasopharyngeal carcinoma NPC 54 effector cells 54 molecularly targeted 54 pancreatic 54 Factor Receptor 54 B Raf 54 immunopathology 54 antitumor activity 54 multiple myeloma 54 FGFR3 54 c MET 54 EBV infection 54 T#I mutant 54 PLX MS 54 anticancer therapeutics 54 cancerdefine 54 Idiopathic Thrombocytopenic Purpura ITP 54 lymphoid tissue 54 malignant lesions 54 APOPTONE 54 anticancer drugs 54 solid organ transplantation 54 histone deacetylase HDAC 54 Ontak 54 exocrine pancreas 54 NovaBay Aganocide compounds 54 Toxicities 54 mutated K ras 54 malignant lymphocytes 54 grade cervical intraepithelial 54 amyloidosis 54 refractory prostate cancer 54 fibrosis 54 radiation chemoradiation 54 tumor suppressor genes 54 schwannomas 54 Nicole Onetto MD 54 Malignant pleural mesothelioma 54 multi kinase inhibitor 54 haematological cancers 54 HDACi 54 genomic alterations 54 Notch1 54 P. aeruginosa infections 54 demonstrated antitumor activity 54 ADVEXIN therapy 54 PCa 54 choroidal neovascularization 54 fungoides 54 adenomatous 54 JAK1 54 PDGF receptor 54 Fibroblast Growth Factor Receptor 54 prognostic biomarker 54 inhibit replication 54 gene amplification 54 DNA methylation patterns 54 tNOX 54 spinal metastases 54 xenograft models 54 mutated protein 54 Vandetanib 54 myeloablative 54 Kinoid 54 proteasome inhibitors 54 metastatic uveal melanoma 54 lung metastasis 54 hemorrhagic fever viruses 54 pancreatic neuroendocrine tumors 54 relapsed leukemia 54 hematologic diseases 54 systemic toxicity 54 antitumor effect 54 proximal tubules 54 non squamous 54 dyskeratosis congenita 54 cancer 54 huntingtin gene 54 leiomyoma 54 bevacizumab Avastin ® 54 promoter hypermethylation 54 PTLD 54 cranial irradiation 54 Hepatocellular carcinoma HCC 54 malignant prostate 54 MAb 54 CEQ# 54 Idiopathic Pulmonary Fibrosis 54 nonmetastatic 54 dirucotide 54 grade cervical dysplasia 54 ISF# 54 Interferon beta 54 transthyretin amyloidosis 53 telomerase inhibition 53 gemcitabine chemotherapy 53 BRAF inhibitor 53 metastasise 53 lung adenocarcinoma 53 humanized antibody 53 imatinib therapy 53 TGF beta signaling 53 hypervascular tumors 53 MELAS 53 neuroblastoma tumor 53 ALK mutations 53 ara C 53 chronic HBV infection 53 grade glioma 53 castrate resistant 53 HER2 receptor 53 annexin 53 Immunohistochemical analysis 53 CMV infections 53 PDGFR 53 node metastases 53 cancer metastasizes 53 erythematosus 53 ENMD # 53 retinal diseases 53 reperfusion injury 53 Systemic lupus erythematosus 53 meningiomas 53 radiotherapeutic 53 localized renal 53 lymphoid tissues 53 myelodysplastic syndromes MDS 53 EGFR expressing 53 esophageal tumors 53 targeted radiotherapeutics 53 tumor xenograft models 53 cytotoxin 53 cystectomy 53 mutated BRAF gene 53 CTEPH 53 sPLA2 53 grade serous ovarian 53 leukemic stem cells 53 Endometrial cancer 53 PARP inhibitor 53 spinal muscular atrophy SMA 53 Bcl2 53 bevacizumab Avastin 53 immunodeficiency diseases 53 latent tuberculosis TB 53 ANCA associated 53 Metastatic melanoma 53 stage IIIA 53 mtDNA mutations 53 ccRCC 53 pancreatic gastric 53 Duchenne muscular dystrophy DMD 53 inhibiting tumor 53 malignant gliomas 53 uveal melanoma 53 myelodysplastic syndromes 53 leukemias 53 xenograft tumors 53 JAK inhibitors 53 AA Amyloidosis 53 hepatocellular 53 lymph nodes spleen 53 Adjuvant chemotherapy 53 vascular abnormalities 53 LHRH receptors 53 PROCHYMAL 53 ALK inhibitors 53 neoadjuvant treatment 53 glial tumors 53 Nedd4 53 bronchogenic carcinoma 53 HBeAg negative 53 Azedra 53 NF1 53 IgG1 antibody 53 percutaneous biopsy 53 NPM1 53 prostate epithelial cells 53 alkylating agent 53 MAbs targeting 53 angiogenesis inhibition 53 mutated KRAS 53 axitinib 53 castration resistant 53 cell lymphoma ALCL 53 lymph node metastases 53 staphylococcal infections 53 adjuvant radiation 53 ON #.Na 53 intracranial hemorrhage ICH 53 glomerulonephritis 53 Aurora kinase 53 platinum refractory 53 MLL AF9 53 lymphomas leukemias 53 neovascularization 53 nodular melanoma 53 hormonal therapies 53 stage IIIB 53 metastatic lung cancer 53 chemopreventive agents 53 lymphocytic 53 lymphadenopathy 53 tumor biopsies 53 hematopoietic malignancies 53 cancerous cells 53 calcineurin 53 membranous nephropathy 53 proteasome inhibitor 53 anticancer treatments 53 BrachySil ™ 53 anaplastic astrocytoma AA 53 elacytarabine 53 biliary tract cancer 53 refractory Hodgkin 53 nucleolin 53 VEGFR 53 P#X# 53 Sjögren syndrome 53 breast tumors 53 choriocarcinoma 53 Nanobodies 53 axonal degeneration 53 viral hemorrhagic fevers 53 Sjogren syndrome 53 Candida infections